Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited released its monthly return for the period ended 30 September 2026, confirming no changes to either authorised or issued share capital during the month.

Authorised / Registered Capital • H-share quota remained at 219.90 million shares with a par value of RMB 1 each, leaving total H-share authorised capital unchanged at RMB 219.90 million. • A-share quota stood at 1.41 billion shares, also at RMB 1 par value, keeping authorised capital at RMB 1.41 billion. • Combined authorised capital therefore held steady at RMB 1.63 billion, equivalent to a total of 1.63 billion ordinary shares.

Issued Shares and Treasury Stock • Issued H shares: 219.90 million; treasury H shares: zero — no movement from the prior month. • Issued A shares: 1.41 billion; treasury A shares: zero — likewise unchanged. • Overall issued share count therefore remained at approximately 1.63 billion, with no issuances, cancellations, conversions, or buybacks recorded.

Public Float • The company confirmed compliance with Hong Kong Main Board Rule 13.32D(1), maintaining a public float of at least 5 % of total issued H shares.

Capital Instruments • No outstanding or newly issued share options, warrants, convertible securities, or other equity-linked instruments were reported for the month.

Governance Confirmation • The company secretary affirmed that all statutory filings and listing rule requirements were met and that no new share-related transactions occurred in September.

The absence of capital movements during the month indicates a stable equity structure, with both Hong Kong-listed H shares and Shanghai-listed A shares unchanged and fully compliant with listing regulations.